The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
Sarfaraz K Niazi College of Pharmacy, University of Illinois, Chicago, IL, USACorrespondence: Sarfaraz K Niazi, Tel +1-312-297-0000, Email niazi@niazi.comAbstract: Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that hu...
Saved in:
Main Author: | Niazi SK (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: AI/ML in pharmacovigilance and pharmacoepidemiology
by: Wen Zou, et al.
Published: (2024) -
A Perspective on a Quality Management System for AI/ML-Based Clinical Decision Support in Hospital Care
by: Richard Bartels, et al.
Published: (2022) -
AI approaches for the discovery and validation of drug targets
by: Aaron Wenteler, et al.
Published: (2024) -
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022) -
The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies
by: Alexandre Blanco-González, et al.
Published: (2023)